CLINICAL_TRIALS
trial_result
· 2023-03-01
Clinical Trial Update: A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 trial of bermekimab in moderate to severe atopic dermatitis was terminated; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Dermatitis, Atopic | Phase 2 | Status: TERMINATED | Results posted: 2023-03-01